Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTswift: Nilotinib in Ph+ CML-CP
NCT02108951Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jul 2014; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02108951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108951.